Campus Units

Chemical and Biological Engineering, Nanovaccine Institute

Document Type


Research Focus Area

Advanced and Nanostructured Materials, Health Care Technology and Biomedical Engineering

Publication Version

Accepted Manuscript

Publication Date


Journal or Book Title

Nanomedicine: Nanotechnology, Biology and Medicine

First Page





The primary objective of this study was to enhance the antitumor efficacy of a model cancer vaccine through co-delivery of pentaerythritol lipid A (PELA), an immunological adjuvant, and a model tumor antigen, ovalbumin (OVA), separately loaded into polyanhydride particles (PA). In vitro experiments showed that encapsulation of PELA into PA (PA-PELA) significantly enhanced its stimulatory capacity on dendritic cells as evidenced by increased levels of the cell surface costimulatory molecules, CD80/CD86. In vivo experiments showed that PA-PELA, in combination with OVA-loaded PA (PA-OVA), significantly expanded the OVA-specific CD8+ T lymphocyte population compared to PA-OVA alone. Furthermore, serum OVA-specific antibody titers of mice vaccinated with PA-OVA/PA-PELA displayed a significantly stronger shift toward a Th1-biased immune response compared to PA-OVA alone, as evidenced by the substantially higher IgG2C:IgG1 ratios achieved by the former. Analysis of E.G7-OVA tumor growth curves showed that mice vaccinated with PA-OVA/PA-PELA had the slowest average tumor growth rate.


This is a manuscript of an article published as Wafa, Emad I., Sean M. Geary, Kathleen A. Ross, Jonathan T. Goodman, Balaji Narasimhan, and Aliasger K. Salem. "Pentaerythritol-based lipid A bolsters the antitumor efficacy of a polyanhydride particle-based cancer vaccine." Nanomedicine: Nanotechnology, Biology and Medicine (2019): 102055. DOI: 10.1016/j.nano.2019.102055. Posted with permission.

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Copyright Owner

Elsevier Inc.



File Format


Published Version